Home  /  Resource Library  /  Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma – Interim Analysis of Phase II Clinical Trial

Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma – Interim Analysis of Phase II Clinical Trial

Interim results of a phase II trial of Ibrutinib, Bendamustine and Rituximab for relapsed diffuse large b-cell lymphoma.